Lower Extremity Bypass Using Bovine Carotid Artery Graft (Artegraft): An Analysis of 124 Cases with Long‐Term Results

Lindsey, Philip; Echeverría, Ángela; Cheung, Mathew; Kfoury, Elias; Bechara, Carlos F.; Lin, Peter H.

doi:10.1007/s00268-017-4161-x

Cited by 30 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outcomes were promising, with patency up to 2 years even if applied in a low-flow district. A recent long-term study (2002–2017) showed the application of a bovine carotid artery graft (Artegraft) in lower extremity bypass surgery (Lindsey et al, 2017 ). Follow-up of 5 years of primary endpoints showed positive results for patency (66.7%) and salvage limb rates (81% of treated cases) (Table 1 ).…”

Section: Tissue Engineeringmentioning

confidence: 99%

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts

Carrabba

Madeddu

2018

Front. Bioeng. Biotechnol.

178

144

View full text Add to dashboard Cite

Occlusive arterial disease, including coronary heart disease (CHD) and peripheral arterial disease (PAD), is the main cause of death, with an annual mortality incidence predicted to rise to 23.3 million worldwide by 2030. Current revascularization techniques consist of angioplasty, placement of a stent, or surgical bypass grafting. Autologous vessels, such as the saphenous vein and internal thoracic artery, represent the gold standard grafts for small-diameter vessels. However, they require invasive harvesting and are often unavailable. Synthetic vascular grafts represent an alternative to autologous vessels. These grafts have shown satisfactory long-term results for replacement of large- and medium-diameter arteries, such as the carotid or common femoral artery, but have poor patency rates when applied to small-diameter vessels, such as coronary arteries and arteries below the knee. Considering the limitations of current vascular bypass conduits, a tissue-engineered vascular graft (TEVG) with the ability to grow, remodel, and repair in vivo presents a potential solution for the future of vascular surgery. Here, we review the different methods that research groups have been investigating to create TEVGs in the last decades. We focus on the techniques employed in the manufacturing process of the grafts and categorize the approaches as scaffold-based (synthetic, natural, or hybrid) or self-assembled (cell-sheet, microtissue aggregation and bioprinting). Moreover, we highlight the attempts made so far to translate this new strategy from the bench to the bedside.

show abstract

Section: Tissue Engineeringmentioning

confidence: 99%

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts

Carrabba

Madeddu

2018

Front. Bioeng. Biotechnol.

178

144

View full text Add to dashboard Cite

show abstract

“…When choosing a conduit for obturator bypass, even though studies have shown that while autologous vein may serve as the best graft, this is not an option in every patient. Lindsey et al found autologous vein was unsuitable for bypass in 72% of patients [5]. PTFE, however, is not the only alternative.…”

Section: Discussionmentioning

confidence: 99%

Obturator Bypass with Bovine Carotid Artery Graft: A Novel Twist to a Traditional Technique

Brown

Esper

Henwood

2019

Case Reports in Surgery

View full text Add to dashboard Cite

When managing an infected groin, though rarely performed, a transobturator bypass remains an important alternative in the armament of a vascular surgeon. Autologous vein and synthetic PTFE are known conduit options for obturator bypasses, although the advantage of utilizing an autologous biological conduit when dealing with infection may not be an option for every patient. On literature review, bovine carotid grafts have been used in infrainguinal revascularizations with comparable results to autologous vein; however, no cases can be found for its use in obturator bypass thus far.

show abstract

“…These poor outcomes were related to inappropriate processing, which resulted in insufficient mechanical properties to support the pressure of the circulatory system 217 and low antigen removal 218 . Having said that, recent reports on bovine artery crosslinked with starch dialdehyde (as opposed to GTA) have shown positive results as haemodialysis access 219 or as lower extremity bypass 220 . However, their implantation is not a generalized procedure, as their performance has not improved synthetic grafting.…”

Section: Xenografts In Clinical Indicationsmentioning

confidence: 99%

Decellularized xenografts in regenerative medicine: From processing to clinical application

Capella-Monsonís

Zeugolis

2021

Xenotransplantation

View full text Add to dashboard Cite

Decellularized xenografts are an inherent component of regenerative medicine. Their preserved structure, mechanical integrity and biofunctional composition have well established them in reparative medicine for a diverse range of clinical indications. Nonetheless, their performance is highly influenced by their source (ie species, age, tissue) and processing (ie decellularization, crosslinking, sterilization and preservation), which govern their final characteristics and determine their success or failure for a specific clinical target. In this review, we provide an overview of the different sources and processing methods used in decellularized xenografts fabrication and discuss their effect on the clinical performance of commercially available decellularized xenografts.

show abstract

Lower Extremity Bypass Using Bovine Carotid Artery Graft (Artegraft): An Analysis of 124 Cases with Long‐Term Results

Abstract: BCAG is an excellent vascular conduit and provides good long-term results in lower extremity bypass.

Cited by 30 publications

References 29 publications

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts

Current Strategies for the Manufacture of Small Size Tissue Engineering Vascular Grafts

Obturator Bypass with Bovine Carotid Artery Graft: A Novel Twist to a Traditional Technique

Decellularized xenografts in regenerative medicine: From processing to clinical application

Contact Info

Product

Resources

About